C.F.R. homeSearch C.F.R.
C.F.R.Title 21Chapter I—Food and Drug Administration, Department of Health and Human ServicesSubchapter D—Drugs for Human UsePart 312—Investigational New Drug ApplicationSubpart A—General Provisions

21 C.F.R. § 312.7 (2026)

Promotion of investigational drugs

Edition and currency
eCFR text as of Sept. 29, 2026. The text is the edition Syfert holds; for a past event, check the version in force on that date.
Other sources
CURRENTeCFR text as of Sept. 29, 2026 cited 1993–2017 7citing cases
At a glance

Courts have cited this section in 7 opinions since 1993.

(a) Promotion of an investigational new drug. A sponsor or investigator, or any person acting on behalf of a sponsor or investigator, shall not represent in a promotional context that an investigational new drug is safe or effective for the purposes for which it is under investigation or otherwise promote the drug. This provision is not intended to restrict the full exchange of scientific information concerning the drug, including dissemination of scientific findings in scientific or lay media. Rather, its intent is to restrict promotional claims of safety or effectiveness of the drug for a use for which it is under investigation and to preclude commercialization of the drug before it is approved for commercial distribution.

(b) Commercial distribution of an investigational new drug. A sponsor or investigator shall not commercially distribute or test market an investigational new drug.

(c) Prolonging an investigation. A sponsor shall not unduly prolong an investigation after finding that the results of the investigation appear to establish sufficient data to support a marketing application.

[52 FR 8831, Mar. 19, 1987, as amended at 52 FR 19476, May 22, 1987; 67 FR 9585, Mar. 4, 2002; 74 FR 40899, Aug. 13, 2009]
The 7 cases that cite 21 C.F.R. § 312.7 most heavily, weighted by court and treatment. RelevanceNewestTreatment
cites § 312.7 4×cited by 45 cases
Where it cites § 312.7
“24 See 21 C.F.R. § 312.7 (a)(prohibiting, inter alia, pharmaceutical 25 companies from “promoting” drugs not yet approved by the FDA).”
The case’s holding
A complaint sufficiently states a claim under the TCPA if it alleges a firm sent an unsolicited fax promoting a free event related to the firm's business.
Later courts cite it for
“the tcpa creates a private right of action, providing for statutory damages in the amount of 500 for each violation as well as injunctive relief against future violations.” · 4 citing courts
2
GREENOrtho Pharm. Corp. v. Cosprophar, Inc., 828 F. Supp. 1114 (S.D.N.Y. 1993).
cites § 312.7 3×cited by 27 cases
Where it cites § 312.7
“21 C.F.R. § 312.7 (1992). For a more detailed discussion, see infra n.”
Later courts cite it for
“the second circuit has limited standing to commercial parties, excluding 'mere consumers” · 2 citing courts
cites § 312.7 1×cited by 58 cases
Where it cites § 312.7
“Cf 21 C.F.R. § 312.7 (prohibiting manufacturer from charging for an investigational new drug in a clinical trial without the prior written approval of the FDA).”
The case’s holding
A relator need not plead every instance of fraud in a complex scheme but must allege the general framework and specific fraudulent conduct with particularity.
Later courts cite it for
“where the alleged scheme of fraud is complex and far-reaching, pleading every instance of fraud would be extremely ungainly, if not impossible. courts facing similar claims under the false claims act have not placed the bar so high as to require pleading with total insight.” · 4 citing courts
4
GREENUnited States ex rel. Zissler v. Regents of the Univ., 992 F. Supp. 1097 (D. Minn. 1998).
cites § 312.7 2×cited by 7 cases
Summary
No passage or summary on file for this case yet.
cites § 312.7 1×cited by 32 cases
Where it cites § 312.7
“34 (b)(3) (preventing access to experimental drugs for terminally ill patients where there is insufficient evidence of effectiveness or where there is an unreasonable risk of injury) and 21 C.F.R. § 312.7 (prohibiting drug manufacturers from profiting on the sale of experimental…”
6
NO FLAGAbigail All. for Better Access v. Von Eschenbach, 495 F.3d 695 (D.C. Cir. 2007).
cites § 312.7 1×cited by 0 cases
Where it cites § 312.7
“34 (b)(3) (preventing access to experimental drugs for terminally ill patients where there is insufficient evidence of effectiveness or where there is an unreasonable risk of injury) and 21 C.F.R. § 312.7 (prohibiting drug manufacturers from profiting on the sale of experimental…”
7
NO FLAGRichard Yocum v. Rockwell Med. Tech., 614 F. App'x 915 (9th Cir. 2015).
cites § 312.7 1×cited by 0 casesunpublished
Where it cites § 312.7
“Yocum has not argued that Rockwell engaged in an actual violation of these regulations. Additionally, although he argues in his briefs that he reasonably believed Rockwell had violated these regulations, he has not presented any evidence that he held those beliefs during the…”

The flag is Syfertize’s treatment of the citing case itself, not of the statute. “Where it cites” is the passage in the opinion; the holding is a summary of the whole case and may concern another point. Annotations are extracted automatically from the opinions in the Syfert caselaw corpus.

Citing cases by year
199320052017

One bar per year. Tallest: 2 cases in 2007. These are opinions in the Syfert collection, which holds more of some courts’ recent opinions than their older ones, so a rise can reflect what the collection holds and not more litigation.

By court
D.C. Cir.22d Cir.19th Cir.1D. Mass.1D. Minn.1S.D.N.Y.1
By subsection

Courts have not cited this section by subsection, so its cases are not split up here. The Leading cases tab lists the cases that cite it most heavily.

Enactment and amendments

Syfert holds no separate history line for this section. Where this code prints a source or history note, it appears with the text, usually at the end.

Versions

Edition shown: eCFR text as of Sept. 29, 2026. Syfert holds no earlier or later version of this section.

C.F.R. Home  |  Search C.F.R.  |  Search cases for this section  |  syfert.com